Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Lipoprotein(a) Is the Best Single Marker in Assessing Unstable Angina Pectoris.

Djordjević VB, Cosić V, Stojanović I, Kundalić S, Zvezdanović L, Deljanin-Ilić M, Vlahović P, Popović L.

Cardiol Res Pract. 2011 Mar 7;2011:175363. doi: 10.4061/2011/175363.

PMID:
21403866
[PubMed]
Free PMC Article
2.

Serum Fas/FasL levels in dependence on clinical presentations of coronary disease and their relationship with risk factors.

Ristić T, Djordjević VB, Deljanin-Ilić M, Cosić V, Kundalić S.

Vojnosanit Pregl. 2010 Jul;67(7):537-42.

PMID:
20707047
[PubMed - indexed for MEDLINE]
3.

Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.

Cubrilo-Turek M, Sertić J, Duraković Z.

Acta Med Croatica. 2001;55(4-5):161-7.

PMID:
12398019
[PubMed - indexed for MEDLINE]
4.

API expert consensus document on management of ischemic heart disease.

Association of Physicians of India.

J Assoc Physicians India. 2006 Jun;54:469-80. Review.

PMID:
16909697
[PubMed - indexed for MEDLINE]
5.

The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.

Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD.

Clin Chem Lab Med. 2004;42(12):1355-63.

PMID:
15576296
[PubMed - indexed for MEDLINE]
6.

Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).

Holme I, Strandberg TE, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.

Atherosclerosis. 2009 Aug;205(2):522-7. doi: 10.1016/j.atherosclerosis.2009.01.023. Epub 2009 Jan 24.

PMID:
19327776
[PubMed - indexed for MEDLINE]
7.

The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease.

Rasouli M, Kiasari AM, Mokhberi V.

Clin Chem Lab Med. 2006;44(8):1015-21.

PMID:
16879071
[PubMed - indexed for MEDLINE]
8.

[Oxidized LDL and lipids as risk factors for ischemic heart disease in type 2 diabetes].

Zamaklar M, Lalić K, Rajković N, Trifunović D, Dragasević M, Popović L, Drasković D, Laić N, Jotić A, Vasović O, Lukić L, Milicić T, Potpara T.

Vojnosanit Pregl. 2005 Jul-Aug;62(7-8):529-36. Serbian.

PMID:
16171015
[PubMed - indexed for MEDLINE]
9.

Lipoprotein (a) is increased in acute coronary syndromes (unstable angina pectoris and myocardial infarction), but it is not predictive of the severity of coronary lesions.

Brunelli C, Spallarossa P, Bertolini S, Balbi M, Barbara C, Masturzo P, Lantieri PB, Pastorini C, Caponnetto S.

Clin Cardiol. 1995 Sep;18(9):526-9.

PMID:
7489610
[PubMed - indexed for MEDLINE]
10.

ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.

Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW.

Curr Med Res Opin. 2008 Feb;24(2):359-64.

PMID:
18081989
[PubMed - indexed for MEDLINE]
11.

ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure.

Kimak E, Solski J.

Ren Fail. 2002 Jul;24(4):485-92.

PMID:
12212828
[PubMed - indexed for MEDLINE]
12.

[Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].

Kuznetsova MA, Vaulin NA, Masenko VP, Gratsianskiĭ NA.

Kardiologiia. 2010;50(2):21-5. Russian.

PMID:
20146674
[PubMed - indexed for MEDLINE]
13.

Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction.

Walter DH, Fichtlscherer S, Britten MB, Auch-Schwelk W, Schächinger V, Zeiher AM.

Am J Cardiol. 2002 Jan 1;89(1):1-6.

PMID:
11779513
[PubMed - indexed for MEDLINE]
14.

Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy.

Hoenig MR, Sellke FW.

Atherosclerosis. 2010 Jul;211(1):260-5. doi: 10.1016/j.atherosclerosis.2010.02.029. Epub 2010 Mar 1.

PMID:
20356594
[PubMed - indexed for MEDLINE]
16.

Lipoprotein (a) blood levels in unstable angina pectoris, acute myocardial infarction, and after thrombolytic therapy.

Qiu SQ, Théroux P, Genest J Jr, Solymoss BC, Robitaille D, Marcil M.

Am J Cardiol. 1991 Jun 1;67(15):1175-9.

PMID:
1827942
[PubMed - indexed for MEDLINE]
17.

Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.

Puzo J, Alfonso P, Irun P, Gervas J, Pocovi M, Giraldo P.

Atherosclerosis. 2010 Apr;209(2):515-9. doi: 10.1016/j.atherosclerosis.2009.10.015. Epub 2009 Oct 17.

PMID:
19959168
[PubMed - indexed for MEDLINE]
18.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

PMID:
16973506
[PubMed - indexed for MEDLINE]
Free Article
19.

Is oxidative stress causally linked to unstable angina pectoris? A study in 100 CAD patients and matched controls.

Kostner K, Hornykewycz S, Yang P, Neunteufl T, Glogar D, Weidinger F, Maurer G, Huber K.

Cardiovasc Res. 1997 Dec;36(3):330-6.

PMID:
9534853
[PubMed - indexed for MEDLINE]
Free Article
20.

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

Genest J Jr, Nguyen NH, Theroux P, Davignon J, Cohn JS.

J Cardiovasc Pharmacol. 2000 Jan;35(1):164-72.

PMID:
10630748
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk